Password forgotten? get a new one
New participant? register now
The RfB is expanding its EQA programme to include the determination of the neurofilament light chain (NfL) in serum. This measurement serves as a biomarker for assessing neuroaxonal damage, particularly in multiple sclerosis. Dates for 2025 are planned for June and November.
You need to load content from hCaptcha to submit the form. Please note that doing so will share data with third-party providers.
More InformationYou need to load content from reCAPTCHA to submit the form. Please note that doing so will share data with third-party providers.
More InformationYou are currently viewing a placeholder content from Turnstile. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
More Information